Kamau Therapeutics is a clinical-stage, next-generation gene correction company harnessing high efficiency targeted gene integration to develop a new class of therapies with the aim to cure a wide range of serious and life-threatening diseases. Our novel gene correction approach, called homology-directed repair (HDR), overcomes prior limitations in specificity, efficiency, and durability of gene editing to offer broad potential for transforming human health outcomes through the delivery of one-time curative cell therapies. Our platform aims treat or cure a range of serious genetic diseases with unmet medical needs.
Company Details
- Employees
- 13
- Address
- South San Francisco, California 94080, Us
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://kamautx.com
- HQ
- South San Francisco, California
Kamau Therapeutics Questions
Kamau Therapeutics's website is http://kamautx.com
Kamau Therapeutics's LinkedIn profile is https://www.linkedin.com/company/kamau-therapeutics
Kamau Therapeutics has
13 employees.
View email and phone details for 13
employees at Kamau Therapeutics.
Kamau Therapeutics's industry is
Biotechnology Research
Kamau Therapeutics's top competitors are
Eligo Bioscience,
Century Therapeutics, Inc,
Maxcyte, Inc.,
Arsenal Biosciences, Inc.,
Exai Bio,
Xaira Therapeutics,
Tilt Biotherapeutics Ltd,
Graphite Bio,
Teton Jax Strategic Advisors,
Tahoe Therapeutics.
Kamau Therapeutics's categories are Biotechnology Research
